60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study design

Richard LWasserman,Helen Leavis,Andras Nagy, Paz Carrasco,Colin Anderson-Smits,Barbara McCoy,Alexander Bauer, Liang-Hui Chu, Immanuel Freedman,Zhaoyang Li

Clinical Immunology（2024）

引用 0|浏览9

暂无评分

关键词

Hyaluronidase-facilitated subcutaneous immunoglobulin 20%,Inborn errors of immunity,Randomized clinical trial,Immunoglobulin replacement therapy,Immunodeficiency treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要